Medicare Enrolled
Dr. Mary Porter, MD
Pulmonary Disease · Savannah, GA
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Porter from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Porter?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Porter
Dr. Mary Porter is a pulmonary disease specialist in Savannah, GA, with 20 years of NPI registration. Based on federal Medicare data, Dr. Porter performed 3,610 Medicare services in 2023. These records do not provide a deduplicated patient total.
Between the years covered by Open Payments, Dr. Porter received a total of $10,557 from 37 pharmaceutical and/or device companies across 594 payment records. A record can group multiple payments. These transfers are publicly reported through CMS Open Payments. Disclosure alone does not establish their effect on care. A reliable breakdown by payment category is not available in this snapshot. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Porter is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years of NPI registration
▲ Top 4% volume in GA
$10,557 industry payments
Medicare Practice Summary — 2023
Medicare Utilization ↗3,610
Medicare services
Top 4% in GA for pulmonary disease
Not available
Unique patients (not deduplicated)
$41
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
732 | $86 | $139 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
536 | $0 | $3 |
| Pulmonary gas exchange test A test to examine how well the lungs exchange gases. |
365 | $37 | $61 |
| Lung volume test using gas dilution or washout A test that measures the amount of air in your lungs by using a gas dilution or washout method. |
364 | $29 | $45 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
356 | $61 | $111 |
| Expiratory airflow and volume test A test that measures the amount of air you can exhale and the speed at which you can breathe it out. It evaluates lung function by assessing expiratory airflow and volume. |
354 | $19 | $37 |
| Spirometry test before and after medication A test that measures the amount of air you can exhale and the speed of your breathing before and after taking a medication. |
180 | $26 | $48 |
| Remote patient monitoring device, 30 days Initial setup of devices for remote monitoring of body functions with daily data transmission or alerts. This service covers the first 30 days of the monitoring period. |
164 | $35 | $54 |
| Exercise-induced lung stress test A test performed to evaluate how the lungs function during physical exertion. It helps identify breathing difficulties or lung conditions that occur specifically when exercising. |
114 | $24 | $34 |
| Overnight continuous oxygen level test This test measures oxygen levels in the blood continuously overnight using a device attached to the ear or finger. |
104 | $16 | $26 |
| Lung cancer screening counseling visit A visit to discuss the need for lung cancer screening using a low-dose CT scan. This service is used to determine eligibility and facilitate shared decision making. |
78 | $27 | $30 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
73 | $9 | $17 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
70 | $110 | $180 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
33 | $126 | $186 |
| Remote patient monitoring management, 20 min/month Management based on results from remote vital sign monitoring for the first 20 minutes per calendar month. |
31 | $36 | $56 |
| Smoking cessation counseling, 4-10 minutes A brief counseling session focused on helping patients quit smoking and tobacco use. The provider spends 4 to 10 minutes discussing strategies and support for cessation. |
23 | $14 | $15 |
| New patient office visit, complex (60-74 min) | 19 | $154 | $221 |
| Telehealth originating site facility fee A fee charged by the facility where a patient is located for telehealth services. This covers the use of the site's equipment and staff to connect with a remote provider. |
14 | $22 | $35 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. These counts do not measure clinical quality or years of experience.
Industry Payment Transparency
Open Payments through 2024 ↗$10,557
Total received (2018-2024)
Avg $1,508/year across 7 years
Top 19% in GA for pulmonary disease
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
37
Companies
594
Payment records
Payments are publicly reported; disclosure does not establish legality · Not evidence of wrongdoing · How to interpret →
Payment categories are unavailable while the source breakdown is being rebuilt. Company and year totals do not identify how much belongs to each category.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$2,396
2023
$1,968
2022
$1,859
2021
$1,146
2020
$701
2019
$1,224
2018
$1,262
Payments by company (2024)
AstraZeneca Pharmaceuticals LP
$780
GlaxoSmithKline, LLC.
$360
Regeneron Healthcare Solutions, Inc.
$249
Takeda Pharmaceuticals U.S.A., Inc.
$188
Amgen Inc.
$120
Grifols USA, LLC
$109
Axsome Therapeutics, Inc.
$81
Pulmonx Corporation
$78
Mylan Specialty L.P.
$72
Insmed, Inc.
$67
United Therapeutics Corporation
$65
HARMONY BIOSCIENCES LLC
$64
Vifor Pharma, Inc.
$35
Harmony Biosciences Llc
$28
Philips North America LLC
$24
GENZYME CORPORATION
$21
Actelion Pharmaceuticals US, Inc.
$18
ANI Pharmaceuticals, Inc.
$18
Merck Sharp & Dohme LLC
$17
Top 3 companies account for 58.0% of 2024 payments
All-time payments by company (2018-2024) ›
AstraZeneca Pharmaceuticals LP
$2,595
GlaxoSmithKline, LLC.
$2,339
Boehringer Ingelheim Pharmaceuticals, Inc.
$714
Mylan Specialty L.P.
$577
Regeneron Healthcare Solutions, Inc.
$551
Grifols USA, LLC
$466
Insmed, Inc.
$313
Takeda Pharmaceuticals U.S.A., Inc.
$296
Axsome Therapeutics, Inc.
$284
Amgen Inc.
$245
Philips Electronics North America Corporation
$226
Sunovion Pharmaceuticals Inc.
$213
United Therapeutics Corporation
$150
Harmony Biosciences LLC
$148
Mallinckrodt Hospital Products Inc.
$148
JAZZ PHARMACEUTICALS INC.
$140
Electromed, Inc.
$132
Pulmonx Corporation
$123
Actelion Pharmaceuticals US, Inc.
$102
Circassia Pharmaceuticals Inc
$91
Inspire Medical Systems, Inc.
$90
GENZYME CORPORATION
$86
Genentech USA, Inc.
$74
HARMONY BIOSCIENCES LLC
$64
HOSPIRA, INC.
$57
Merck Sharp & Dohme LLC
$47
ANI Pharmaceuticals, Inc.
$40
Vifor Pharma, Inc.
$35
Jazz Pharmaceuticals Inc.
$35
Harmony Biosciences Llc
$28
Teva Pharmaceuticals USA, Inc.
$28
Shionogi Inc
$27
PFIZER INC.
$25
Philips North America LLC
$24
IDORSIA PHARMACEUTICALS US INC
$17
Fisher & Paykel Healthcare Inc
$14
Merck Sharp & Dohme Corporation
$11
Top 3 companies account for 53.5% of all-time payments
Associated products mentioned in payments ›
(8874) InCourage · (8874) inCourage · (AK6) Vest Therapy · ACTHAR · AIRSUPRA · ANORO · ANORO ELLIPTA · AREXVY · AirDuo Digihaler · Arikayce · BELSOMRA · BREO · BREZTRI · BREZTRI AEROSPHERE · BROVANA · CHARTIS CATHETER · CINQAIR · CUTAQUIG · DIFICID · DUAKLIR PRESSAIR · DUPIXENT · DUPIXENT DUPILUMAB INJECTION · Dymista · Esbriet · FARXIGA · FASENRA · Fetroja · GLASSIA · INSPIRE · LONHALA MAGNAIR · NUCALA · OFEV · OPSUMIT · Obstructive Sleep Apnea Device or Hospital Respiratory Equipment · PANZYGA · PREVNAR 20 · PURIFIED CORTROPHIN GEL · Prolastin-C · Prolastin-C Liquid · QUVIVIQ · Respiratoriy Care Undiv · SHINGRIX · SMARTVEST · SPIRIVA RESPIMAT · STIOLTO RESPIMAT · SUNOSI · SYMBICORT · SYNAGIS · Sunosi · TEZSPIRE · TRELEGY ELLIPTA · TUDORZA PRESSAIR · TYVASO · Trilogy 100 · UPTRAVI · UTIBRON · Utibron · WAKIX · XYREM · XYWAV · Xolair · YUPELRI · Yupelri · ZERBAXA · Zemaira · inCourage
Should you be concerned? Industry payments are disclosed through CMS Open Payments. Disclosure alone does not establish their purpose, legality, or effect on care. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Geographic Context
Pulmonary diseases in nearby ZIP areas
17
County median income
$69,575
Nearest hospital to ZIP centroid (approximate)
COASTAL HARBOR TREATMENT CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | NPPES snapshot; verify current record |
| Medicare Enrollment | ✓ PECOS | PECOS snapshot |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not included | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Porter is a clinical cardiology specialist, with above-average Medicare volume (top 4% in GA), with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Porter experienced with office visit, established patient (30-39 min)?
Based on Medicare claims data, Dr. Porter performed 732 office visit, established patient (30-39 min) services. These records cover Medicare fee-for-service activity, including eligible younger beneficiaries; they do not measure total practice volume or clinical quality.
Does Dr. Porter receive payments from pharmaceutical companies?
Yes. Dr. Porter received a total of $10,557 from 37 companies across 594 payment records. A record can group multiple payments. These transfers are publicly disclosed through CMS Open Payments. Disclosure alone does not establish their legality or effect on care. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Porter's costs compare to other pulmonary diseases in Savannah?
Dr. Porter's average Medicare payment per service is $41. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Porter) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating the presence of registry, enrollment, activity or payment records, not verified experience or clinical quality. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Source publication dates and the snapshots loaded on this site can differ. Rebuilding a page does not refresh its source records. Check the Medicare reporting year and the payment interval shown above; consult the linked official sources for newer releases and current registry details. See our data freshness policy →
Explore related providers
Specialty guide
Understanding Pulmonary Disease
Common procedures, typical costs, and what industry payments mean in pulmonary disease.
Same specialty & city
Pulmonary Diseases in Savannah
Browse pulmonary diseases in Savannah ranked by procedure volume and transparency data.
Highest volume
Top Pulmonary Diseases in GA
Pulmonary diseases ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Pulmonary Diseases in GA
Which GA pulmonary diseases receive the most from drug and device companies.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
GlaxoSmithKline, LLC. Payments to Doctors
See all physicians who received payments from GlaxoSmithKline, LLC.
By company
Boehringer Ingelheim Pharmaceuticals, Inc. Payments to Doctors
See all physicians who received payments from Boehringer Ingelheim Pharmaceuticals, Inc.
About this page
This page combines public CMS records with calculated summaries and explanatory procedure labels. These transformations are not verbatim federal records. Sources: NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology